Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Friday, January 16, 2015

NICE backs new hepatitis C treatments

Two drugs that represent a major advance in hepatitis C are set to be routinely available on the NHS in England and Wales, after NICE issued final draft guidance recommending both Gilead Sciences' Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir) to treat people with the infection.

Both drugs were approved in Europe in 2014 based on impressive clinical data and have gone on to record substantial sales, helped by the fact that both Olysio and Sovaldi were approved as part of shorter oral regimens that do not require the use of interferon, an injection that needs to be taken over several months.

However, both Gilead and Janssen expressed disappointment with some aspects of the NICE guidance.

Read more...

No comments:

Post a Comment